Nab-Paclitaxel Outduels Paclitaxel in HR+/HER2- and Triple-Negative MBC

Article

Among patients with HR+/HER2- or triple-negative metastatic breast cancer, nab-paclitaxel (Abraxane) improved time to treatment discontinuation, time to next treatment, and had a favorable safety profile compared with paclitaxel.

Fadi Braiteh, MD

Among patients with HR+/HER2- or triple-negative metastatic breast cancer, nab-paclitaxel (Abraxane) improved time to treatment discontinuation (TTD), time to next treatment (TTNT), and had a favorable safety profile compared with paclitaxel, according to a real-world database analysis presented at the 33rd Annual Miami Breast Cancer Conference®.

Nab-paclitaxel is approved by the FDA for use in patients with metastatic breast cancer (MBC) following the failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The approval was based on a pivotal phase III trial that showed an overall response rate of 33% with nab-paclitaxel versus 19% with paclitaxel (P = .001) in the frontline or later settings. The median time to progression was 5.3 months versus 3.9 months, respectively (P = .006).

Despite this approval, there is a paucity of comparative effectiveness data in the real-world setting for subsets of patients with MBC who are HR+/HER2- or triple-negative. For this reason, Fadi Braiteh, MD, University of Nevada School of Medicine, and colleagues conducted a retrospective analysis comparing use of nab-paclitaxel versus paclitaxel in these breast cancer subtypes.

Braiteh et al examined data from an electronic medical record platform (Navigating Cancer). Their analysis included patients with HR+/HER2- (n = 446) or triple-negative MBC (n = 228) who received first- or second-line treatment with nab-paclitaxel or paclitaxel between December 1, 2010, and October 1, 2014.

The analysis included only patients treated in a real-world setting, not in clinical trials. Monotherapy was preferred, but patients were still included if they received combination regimens with a targeted agent. Patients received at least 2 doses of nab-paclitaxel or paclitaxel. Individuals were excluded if they received nab-paclitaxel and/or paclitaxel sequentially as first- and second-line therapy.

Nab-paclitaxel was administered at the FDA-approved dose of 260 mg/m2 every 3 weeks, or 100 mg/m2 or 150 mg/m2 once per week for 3 of 4 weeks. Patients received paclitaxel at 175 mg/m2 every 3 weeks or 80 mg/m2 weekly.

In the HR+/HER2- group, 172 patients received nab-paclitaxel, 58% in the first-line and 42% in the second line. Among the 274-patient paclitaxel cohort, 49% received the drug in the first line and 51% received it in the second line. Eighty-one percent and 95% of the nab-paclitaxel and paclitaxel groups, respectively, received the treatment weekly.

Incidence of lung, liver, and brain metastases were even between the arms; however, bone metastases was higher in the nab-paclitaxel arm at 89% versus 61%. Targeted therapy use was even at 6% in both arms, as was prior chemotherapy within 1 year, at 11% versus 8% in the nab-paclitaxel versus paclitaxel arms, respectively.

In the triple-negative breast cancer (TNBC) group, 95 patients received nab-paclitaxel, 81% in the first-line and 19% in the second line. Among the 133-patient paclitaxel cohort, 47% received the drug in the first line and 53% received it in the second line. Eighty-six percent and 96% of the nab-paclitaxel and paclitaxel groups, respectively, received the treatment weekly.

Incidence of lung, liver, and brain metastases were even between the arms; however, bone metastasis was higher in the nab-paclitaxel arm at 65% versus 37%. Targeted therapy use was comparable at 10% versus 7%, as was prior chemotherapy within 1 year, at 23% versus 17%.

In the HR+/HER2- TTD was significantly longer with nab-paclitaxel at 4.5 months versus 2.9 months with paclitaxel (P <.001). The median TTNT was significantly improved with nab-paclitaxel at 6.9 versus 5.3 months, respectively (P <.001).

The TTD was also significantly longer with nab-paclitaxel in the TNBC cohort at 3.3 versus 2.8 months with paclitaxel (unadjusted P = .005). The median TTNT with nab-paclitaxel was numerically higher; however, the difference was not statistically significant: 6.2 versus 5.4 months (unadjusted P = .580).

Across both the HR+/HER2- and TNBC cohorts, neuropathy rates were lower and antiemetics and treatments for allergic reactions to doses were used less frequently among patients receiving nab-paclitaxel. Treatment for bone loss, G-CSF, and hydrating agents were used less frequently with paclitaxel versus nab-paclitaxel.

In the HR+/HER2- arm, notable all-grade adverse events (AEs) with nab-paclitaxel versus paclitaxel included anemia (26% vs 33%), neutropenia (19% vs 14%), nausea and vomiting (12% vs 10%), pain (1% vs 11%), neuropathy (3% vs 8%), and dehydration (9% vs 7%).

The all-grade AE rates were comparable for nab-paclitaxel versus paclitaxel in the TNBC arm: anemia (24% vs 35%), neutropenia (18% vs 12%), nausea and vomiting (12% vs 5%), pain (5% vs 7%), neuropathy (1% vs 11%), and dehydration (15% vs 5%).

<<<

View more from the 33rd Annual Miami Breast Cancer Conference

Related Videos
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "
Don S. Dizon, MD
Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD
Patrick I. Borgen, MD
Henry Kuerer, MD, PhD, FACS, CMQ
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania